Inpatient Update okładka

Inpatient Update

Inpatient Update

Autor: Mason Turner MD
Słuchaj bezpłatnie, bez subskrypcji

Das größte Angebot der Saison | 0,99 € pro Monat für die ersten 3 Monate + 15 € Audible-Guthaben

Danach 6,99 €/Monat. Bedingungen gelten. Monatlich kündbar.
O tym tytule

Inpatient Update delivers short, practical reviews of new studies and guidelines that matter to hospitalists — focused on what actually changes decisions on rounds tomorrow.


Get the key takeaways, cited article links, and episode summaries by email: subscribe.inpatientupdate.com


Efficient, evidence-based, and built for the working hospitalist.

© 2026 Inpatient Update
Higiena i zdrowy tryb życia
  • Reverse, Double Down, or Skip? Salt Restriction, Fosfomycin & Monitors After Syncope
    Nov 18 2026
    With Special Guest Dr. Austin WhiteDr. Austin White returns to Inpatient Update to rethink three everyday decisions:ESBL UTIs: Could oral fosfomycin get your patient home without a PICC?Unexplained syncope: Should more patients leave with a cardiac monitor?Heart failure: Does that automatic low-sodium diet order actually help?Plus, we break out the UNO cards to decide which findings change our practice, which make us double down, and which leave us waiting for more evidence. ArticlesFosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by ESBL-Producing EnterobacteralesClinical Infectious Diseases, 2026Randomized trial of 299 adults improving after 3–7 days of IV antibiotics for complicated ESBL UTIs.Oral fosfomycin 3 g daily vs continued IV therapy; 10 total treatment days.Clinical cure: 92.8% vs 95.2%; met noninferiority.Tested oral step-down after initial IV treatment.TakeawayCheck oral options before ordering a PICC. Susceptible TMP-SMX or fluoroquinolones remain preferred. Consider fosfomycin for selected, improving patients with ESBL E. coli UTIs when those agents aren’t options. IDSA advises against oral fosfomycin step-down for ESBL bloodstream infections.Related guidance: IDSA AMR Guidance, 2026 · IDSA Complicated UTI Guideline, 2025Immediate Ambulatory Electrocardiographic Monitoring in SyncopeNew England Journal of Medicine, 2026 — ASPIREDRandomized trial of 2,234 adults with unexplained syncope after ED evaluation: immediate 14-day ECG monitoring vs usual care.Primary outcome: No significant reduction in syncope episodes at one year.Clinically significant arrhythmias detected: 22% vs 9%.Mortality: 1.5% vs 2.9% — an exploratory secondary finding that needs confirmation. Secondary analyses were not adjusted for multiple comparisons.TakeawayFor selected patients with unexplained syncope and concern for arrhythmia, arrange monitoring before discharge and establish who will review the results.Related guidance: 2017 ACC/AHA/HRS Syncope GuidelineThings We Do For No Reason™: Low Salt Diets for Patients With Acute Heart FailureJournal of Hospital Medicine, 2026A review of routine sodium restriction in acute heart failure.Small inpatient trials have not shown better decongestion or clinical outcomes.Aggressive sodium/fluid restrictions caused more thirst and sometimes lower caloric intake.Outpatient sodium reduction may improve symptoms or quality of life, but randomized evidence has not demonstrated fewer hospitalizations or deaths.TakeawayReconsider the automatic 2-g sodium restriction. Prioritize diuresis, nutrition, and a plan that fits how the patient eats at home.Related guidance:2022 AHA/ACC/HFSA Heart Failure Guideline — avoid excessive sodium for congestive symptoms; no universal HF sodium target.2024 HFA/ESC Consensus on Dietary Sodium and Fluid Intake — source of the 1.5–4 g/day sodium range discussed.Practice-Changing TakeawaysESBL UTIs: Review oral options before committing to outpatient IV antibiotics.Unexplained syncope: When monitoring is indicated, get it started before the patient leaves.Heart failure: Reassess the default sodium restriction and prioritize decongestion and nutrition.Want the cited articles and key takeaways by email? Join the Inpatient Update email list.If this episode was useful, share it with one colleague who takes care of hospitalized patients.Support the showWant the cited articles and key takeaways? Join the email list:https://subscribe.inpatientupdate.com/
    Rozwiń Zwiń
    30 min
  • Before They Leave: The 2026 Hospitalist Vaccine Update
    Sep 16 2026
    We treat flu, RSV, COVID and pneumococcal pneumonia in the hospital. Are we doing enough to prevent the next admission?In this episode of Inpatient Update, Dr. Mason Turner reviews the vaccine decisions hospitalists should be making before discharge: who qualifies, what has changed, and when a hospitalization is an appropriate opportunity to vaccinate.Along the way, we revisit an eye-opening heart failure trial with Dr. Emily Reams, listen to the public ACIP deliberations behind expanded vaccine recommendations, and discuss how evidence-based recommendations fit with shared decision-making.1. Flu vaccination belongs on the discharge checklist.In PANDA II, hospitals in China were randomized to offer free influenza vaccination before discharge or provide usual care for patients hospitalized with acute heart failure and NYHA class III–IV symptoms.Death or readmission within one year occurred in 41.2% versus 47.0% of patients—an absolute difference of approximately 5.8 percentage points, or NNT ≈18 for the composite outcome in this study population.Anderson CS, et al. Influenza vaccination to improve outcomes for patients with acute heart failure—PANDA II. Lancet. 2025;406:1020–1031.Practice change: Offer eligible, clinically appropriate patients their seasonal flu vaccine before discharge. September–October is ideal for most adults, but vaccination remains appropriate later while influenza circulates. CDC influenza guidance.2. RSV vaccination now includes high-risk adults starting at age 50.A single dose is recommended for previously unvaccinated adults:Age 75 and olderAge 50–74 with increased risk of severe RSV disease, including conditions such as heart failure, coronary artery disease, COPD and asthmaRSV vaccination is not currently annual. Review the full risk criteria and prior vaccination history. CDC RSV guidance.The expanded DAN-RSV randomized trial found approximately 70% protection against RSV-related respiratory hospitalization.Lassen MC, et al. Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults. NEJM Evidence. Published August 29, 2026.3. Pneumococcal vaccination starts at 50—or earlier with qualifying risk factors.Assess vaccination status in all adults age 50 and older, and adults 19–49 with qualifying conditions, including diabetes, cigarette smoking, alcohol use disorder, chronic lung disease and chronic heart disease.The appropriate vaccine and schedule depend on previous doses. Review the vaccine history and coordinate with pharmacy. CDC pneumococcal recommendations.Kobayashi M, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years. MMWR. 2025;74:1–8.4. COVID protection needs updating, even in previously vaccinated patients.This episode follows the AAFP’s 2026–2027 recommendations: an updated COVID vaccine for adults, with two seasonal doses six months apart for adults age 65 and older. The linked guidance covers nonpregnant, immunocompetent adults; pregnancy and immunocompromise have separate recommendations. AAFP 2026–2027 respiratory vaccine guidance.In the observational VISION study, receipt of the 2025–2026 vaccine was associated with 53% effectiveness against COVID-related hospitalization in immunocompetent adults age 65 and older.Wiegand RE, et al. Interim Estimated Effectiveness of 2025–2026 COVID-19 Vaccines in Adults Using a Test-Negative Design. JAMA Network Open. 2026;9:e2625152.The updated Pfizer 2026–2027 formulation received FDA approval on August 27, 2026. Check local availability and product eligibility with pharmacy.5. Hospitalization itself is not a reason to defer vaccination.Moderate or severe acute illness is a precaution, but once the patient improves, hospitalization or discharge can be an appropriate opportunity to vaccinate. Make vaccine history and eligibility part of discharge planning. CDC contraindications and precautions.Featured audio and further listeningFrom Inside Family Medicine, produced by the American Academy of Family Physicians:How we create vaccine guidance — September 14, 2026. Drs. Margot Savoy and Danielle Carter explain the AAFP’s current process for developing vaccine recommendations. Recommended listening in this episode.AAFP Fall Immunizations Recommendations — September 16, 2025. Includes the featured excerpt from Dr. Margot Savoy on evidence-based recommendations and shared decision-making.Also featured:Inpatient Update: SHM 2026 Takeaways with Dr. Emily Reams—our original discussion of influenza vaccination in heart failure.CDC/ACIP public meeting excerpts: RSV, April 2025; pneumococcal vaccination, October 2024; vaccination during hospitalization, October 2014.Take a vaccine history. Check eligibility. Offer indicated vaccines before discharge.Get Inpatient Update’s article links and practice-changing takeaways by email.Support the showWant the cited articles and key takeaways? Join the email list:https://...
    Rozwiń Zwiń
    23 min
  • IV Phenobarb + 3 Hospitalist Bad Habits: PPIs, Apixaban & Ceftriaxone
    Aug 27 2026
    In this episode of Inpatient Update, Dr. Mason Turner is joined by clinical pharmacist Lindsay Deloney for one big question and three pharmacy quick hits:Phenobarbital for alcohol withdrawal — can we safely use a structured IV pathway on the medical floor?Steroids + PPIs — does starting glucocorticoids really require gastroprotection?Extended anticoagulation — should apixaban 5 mg twice daily live on the medication list forever after a VTE?AmpC organisms — when should a ceftriaxone-susceptible result actually make you nervous?Practical pharmacology, evidence, and a little pharmacist gentle guidance for your next day on service.ArticlesHospital-Wide Implementation, Clinical Outcomes, and Safety of Phenobarbital for Alcohol WithdrawalJAMA Network Open, 2025https://doi.org/10.1001/jamanetworkopen.2025.28694Hospital-wide implementation of a weight-based IV phenobarbital pathway was associated with:Faster improvement in withdrawal symptoms~30 hours shorter treatment duration~2.2 days shorter time to dischargeNo significant increase in intubation, mortality, or other measured safety outcomesTakeawayPhenobarbital does not have to be an ED- or ICU-only medication.The evidence is observational, but a structured, protocolized approach appears feasible on the medical floor.Steroids + PPI ProphylaxisPrescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia RheumaticaArthritis & Rheumatology, 2026https://doi.org/10.1002/art.70087Gastroprotection with a PPI or H2 blocker was not associated with fewer serious GI events in patients receiving glucocorticoids.Things We Do for No Reason™: Routine Use of Proton Pump Inhibitors for Peptic Ulcer Prophylaxis in Adults on High-Dose CorticosteroidsJournal of Hospital Medicine, 2023https://doi.org/10.1002/jhm.13095TakeawaySteroids alone are not an automatic indication for a PPI.Instead, look for actual GI risk factors: NSAIDs, anticoagulation, antiplatelets, previous GI bleeding, or another independent indication for acid suppression.Extended Anticoagulation After VTEApixaban for Extended Treatment of Venous Thromboembolism — AMPLIFY-EXTNew England Journal of Medicine, 2013https://doi.org/10.1056/nejmoa1207541Extended Reduced-Dose Apixaban for Cancer-Associated VTE — API-CATNew England Journal of Medicine, 2025https://doi.org/10.1056/nejmoa2416112Apixaban for Extended Treatment of Provoked Venous Thromboembolism — HI-PRONew England Journal of Medicine, 2025https://doi.org/10.1056/nejmoa2509426RENOVE TrialLancet, 2025https://doi.org/10.1016/s0140-6736(24)02842-3TakeawayDon’t let apixaban 5 mg twice daily remain on the medication list indefinitely without asking why.After the acute VTE treatment period, reassess:Does this patient still need extended anticoagulation?If so, do they still need full-dose therapy?Could reduced-dose anticoagulation preserve benefit while reducing bleeding risk?The answer depends on recurrence risk, but hospitalization is a great opportunity to revisit the plan.IDSA 2024 Guidance on Antimicrobial-Resistant Gram-Negative Infectionshttps://doi.org/10.1093/cid/ciae403For organisms at meaningful risk of inducible AmpC:Enterobacter cloacae complexKlebsiella aerogenesCitrobacter freundiiA susceptibility report showing “sensitive” to ceftriaxone does not necessarily mean you should use it for an invasive infection.TakeawayRemember the AmpC bugs.For invasive infections with these organisms:Avoid reflexive ceftriaxonePiperacillin-tazobactam is also not preferredCefepime is generally the preferred option when appropriateDon’t just read the susceptibility result. Know the organism.Practice-Changing TakeawaysAlcohol withdrawal: Phenobarbital can be used beyond the ICU when supported by a structured pathway.Steroids: Don’t automatically add a PPI.VTE: Reassess chronic full-dose apixaban once the acute treatment period is over.AmpC: Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii — don’t let a ceftriaxone “S” fool you.Question the medication list. Know the organism. Use your pharmacist.Support the showWant the cited articles and key takeaways? Join the email list:https://subscribe.inpatientupdate.com/
    Rozwiń Zwiń
    31 min
adbl_web_anon_alc_button_suppression_t1
Brak recenzji